These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 24289998)

  • 1. Does progesterone elevation compromise pregnancy rates in high responders? Insufficient evidence to draw a conclusion.
    Bosch E
    Fertil Steril; 2014 Jan; 101(1):e3-4. PubMed ID: 24289998
    [No Abstract]   [Full Text] [Related]  

  • 2. Reply of the authors.
    Griesinger G; Mannaerts B; Andersen CY; Witjes H; Kolibianakis EM; Gordon K
    Fertil Steril; 2014 Jan; 101(1):e5-6. PubMed ID: 24289995
    [No Abstract]   [Full Text] [Related]  

  • 3. Progesterone elevation does not compromise pregnancy rates in high responders: a pooled analysis of in vitro fertilization patients treated with recombinant follicle-stimulating hormone/gonadotropin-releasing hormone antagonist in six trials.
    Griesinger G; Mannaerts B; Andersen CY; Witjes H; Kolibianakis EM; Gordon K
    Fertil Steril; 2013 Dec; 100(6):1622-8.e1-3. PubMed ID: 24083873
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized controlled trial of increasing recombinant follicle-stimulating hormone after initiating a gonadotropin-releasing hormone antagonist for in vitro fertilization-embryo transfer.
    Propst AM; Bates GW; Robinson RD; Arthur NJ; Martin JE; Neal GS
    Fertil Steril; 2006 Jul; 86(1):58-63. PubMed ID: 16753156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is a premature rise in luteinizing hormone in the absence of increased progesterone levels detrimental to pregnancy outcome in GnRH antagonist in vitro fertilization cycles.
    Dovey S; McIntyre K; Jacobson D; Catov J; Wakim A
    Fertil Steril; 2011 Sep; 96(3):585-9. PubMed ID: 21774931
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characteristics of progesterone changes in women with subtle progesterone rise in recombinant follicle-stimulating hormone and gonadotropin-releasing hormone antagonist cycle.
    Seow KM; Lin YH; Hsieh BC; Huang LW; Huang SC; Chen CY; Chen PH; Tzeng CR; Hwang JL
    Gynecol Obstet Invest; 2010; 70(1):64-8. PubMed ID: 20203521
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Defining the "sweet spot" for administered luteinizing hormone-to-follicle-stimulating hormone gonadotropin ratios during ovarian stimulation to protect against a clinically significant late follicular increase in progesterone: an analysis of 10,280 first in vitro fertilization cycles.
    Werner MD; Forman EJ; Hong KH; Franasiak JM; Molinaro TA; Scott RT
    Fertil Steril; 2014 Nov; 102(5):1312-7. PubMed ID: 25150393
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral contraceptive pill pretreatment in ovarian stimulation with GnRH antagonists for IVF: a systematic review and meta-analysis.
    Griesinger G; Venetis CA; Marx T; Diedrich K; Tarlatzis BC; Kolibianakis EM
    Fertil Steril; 2008 Oct; 90(4):1055-63. PubMed ID: 18054003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effectiveness of gonadotropin-releasing hormone antagonist in poor ovarian responders undergoing in vitro fertilization: a systematic review and meta-analysis.
    Xiao J; Chang S; Chen S
    Fertil Steril; 2013 Dec; 100(6):1594-601.e1-9. PubMed ID: 24055048
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GnRH agonist versus GnRH antagonist in ovarian stimulation: the role of elevated peak serum progesterone levels.
    Orvieto R; Nahum R; Meltzer S; Liberty G; Anteby EY; Zohav E
    Gynecol Endocrinol; 2013 Sep; 29(9):843-5. PubMed ID: 23802563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Subtle progesterone rise in the single-dose gonadotropin-releasing hormone antagonist (cetrorelix) stimulation protocol in patients undergoing in vitro fertilization or intracytoplasmic sperm injection cycles.
    Seow KM; Lin YH; Huang LW; Hsieh BC; Huang SC; Chen CY; Chen PH; Tzeng CR; Hwang JL
    Gynecol Endocrinol; 2007 Jun; 23(6):338-42. PubMed ID: 17616858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel protocol of ovulation induction with delayed gonadotropin-releasing hormone antagonist administration combined with high-dose recombinant follicle-stimulating hormone and clomiphene citrate for poor responders and women over 35 years.
    D'Amato G; Caroppo E; Pasquadibisceglie A; Carone D; Vitti A; Vizziello GM
    Fertil Steril; 2004 Jun; 81(6):1572-7. PubMed ID: 15193479
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Can we skip weekends in GnRH antagonist cycles without compromising the final outcome?
    Bosch E
    Fertil Steril; 2012 Jun; 97(6):1299-300. PubMed ID: 22656307
    [No Abstract]   [Full Text] [Related]  

  • 14. Minimal stimulation using gonadotropin-releasing hormone (GnRH) antagonist and recombinant human follicle-stimulating hormone versus GnRH antagonist multiple-dose protocol in low responders undergoing in vitro fertilization/intracytoplasmic sperm injection.
    Kim CH; Kim SR; Cheon YP; Kim SH; Chae HD; Kang BM
    Fertil Steril; 2009 Dec; 92(6):2082-4. PubMed ID: 19589522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reproductive outcomes after a single dose of gonadotropin-releasing hormone agonist compared with human chorionic gonadotropin for the induction of final oocyte maturation in hyper-responder women aged 35-40 years.
    Tannus S; Turki R; Cohen Y; Son WY; Shavit T; Dahan MH
    Fertil Steril; 2017 Jun; 107(6):1323-1328.e2. PubMed ID: 28501366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum and follicular endocrine profile is different in modified natural cycles than in cycles stimulated with gonadotropin and gonadotropin-releasing hormone antagonist.
    Jancar N; Virant-Klun I; Bokal EV
    Fertil Steril; 2009 Dec; 92(6):2069-71. PubMed ID: 19815198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Agonist or antagonist: what is preferable for in vitro fertilization?
    Ben-Rafael Z
    Gynecol Endocrinol; 2012 Mar; 28 Suppl 1():18-21. PubMed ID: 22394299
    [No Abstract]   [Full Text] [Related]  

  • 18. Basal serum progesterone and history of elevated progesterone on the day of hCG administration are significant predictors of late follicular progesterone elevation in GnRH antagonist IVF cycles.
    Venetis CA; Kolibianakis EM; Bosdou JK; Lainas GT; Sfontouris IA; Tarlatzis BC; Lainas TG
    Hum Reprod; 2016 Aug; 31(8):1859-65. PubMed ID: 27301360
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of luteinizing hormone administration on gonadotropin-releasing hormone antagonist cycles: an age-adjusted analysis.
    Bosch E; Labarta E; Crespo J; Simón C; Remohí J; Pellicer A
    Fertil Steril; 2011 Mar; 95(3):1031-6. PubMed ID: 21067717
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of poor responders: can outcomes be improved with a novel gonadotropin-releasing hormone antagonist/letrozole protocol?
    Schoolcraft WB; Surrey ES; Minjarez DA; Stevens JM; Gardner DK
    Fertil Steril; 2008 Jan; 89(1):151-6. PubMed ID: 17482177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.